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LETTERS TO THE EDITOR
High dialysate calcium may
improve the efficacy of
calcimimetic treatment in
hemodialysis patients with
severe secondary
hyperparathyroidism
To the Editor: In a recent issue of Kidney International,
Szczech et al [1] indicated that in the cinacalcet phase III
studies “management of phosphorus binders and vitamin
D sterols were left to the clinical discretion of the site in-
vestigators in each of these trials,” and in this context, the
doses of phosphate binders and vitamin D analogs were
not significantly different during the study and between
study groups. In our opinion, this statement is an over-
simplification. The hemodialysis patients of these trials
[2–4] had inadequately controlled hyperparathyroidism
despite optimal standard treatment. They were assigned
to receive cinacalcet or placebo to achieve intact parathy-
roid hormone (iPTH) serum values of ≤250 pg/mL. A
modification of phosphate binder or vitamin D analog
doses was only permitted if plasma iPTH, calcium, or
phosphorus were outside the normal range. The optimal
combination of these compounds and dialysate calcium
has not been specifically assessed in these studies.
We evaluated the possible importance of a high
dialysate calcium concentration. We administered
cinacalcet for 6 months to 7 chronic hemodialysis pa-
tients with severe secondary hyperparathyroidism, using
a dialysate calcium concentration of 1.75 mmol/L. The av-
erage reduction of plasma parathyroid hormone (PTH)
obtained was 60% (Fig. 1), with only 30 mg/day of cinacal-
cet in 6 patients, and 60 mg/day in 1 and low doses of cal-
cium carbonate, sevelamer, and/or alfacalcidol. Plasma
calcium and phosphorus decreased slightly.
Thus, severe secondary uremic hyperparathyroidism
can be controlled with small doses of cinacalcet in pa-
tients on high calcium dialysate, together with moderate
doses of oral calcium and vitamin D.
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Reply from the Authors
The authors of this letter provide additional detail to my
summary of the trials comparing cinacalcet to placebo [1].
They are correct in that these trials were not specifically
designed to assess the optimal combination of cinacalcet,
vitamin D analogs, and phosphorus binders [2–4]. To the
extent that each protocol allowed changes in the latter 2
groups of medications, there were no differences between
study groups. The data presented by the authors of this
letter are compelling and suggest an additional avenue to
pursue toward defining potential strategies for the control
of secondary hyperparathyroidism.
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Association of reduced red
blood cell deformability and
diabetic nephropathy
To the Editor: In a recent issue of Kidney International,
Brown et al [1] reported significant data concerning red
blood cell deformability and and renal function decline
in type 2 diabetic patients. They propose a smart phys-
iopathologic explanation using the “AGEs” hypothesis
that seems relevant and convincing. However, one can
suppose that AGEs are not the only pathway involved in
both reduction of red blood cell deformability and pro-
gression of renal failure in this population. Indeed, red
blood cell deformability is reduced in diabetic patients [2,
3]. This reduction is correlated with a decrease in Na,K-
ATPase activity in red blood cells. The reduction of both
Na,K-ATPase activity and red blood cell deformability is
proportional to the simultaneous decrease in C-peptide
plasma concentration in type 2 diabetic patients [4] and
can be corrected by C-peptide administration [5]. Besides
being related to NO-mediated direct effects on the re-
sistance vessels, C-peptide’s circulatory effects involve
rheologic factors. This effect is blockable by ouabain,
indicating that it is mediated in part by a restoration
of erytheocyte Na,K-ATPase activity [6]. Furthermore,
C-peptide is involved in stimulation of eNOS in renal
capillary endothelial cells [7], which may modify the
glomerular function, including diminished albumin ex-
cretion. Improved renal function may also be a con-
sequence of stimulation by C-peptide of glomerular or
tubular Na+, K+-ATPase activity [8, 9]. Last, but not
least, a clinical study of a large cohort of type 2 dia-
betic patients showed that onset of diabetic nephropathy
was correlated with the residual plasma C-peptide levels
[10]. Altogether, these are strong arguments to complete
Brown’s “AGEs” hypothesis by measuring C-peptide lev-
els in a future study in this population.
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Reply from the Authors
We wish to thank Rebsomen and Tsimaratos for their
interest in our study, and would like to respond to points
raised in their letter to the Editor. While we recognize
that Na,K-ATPase activity influences RBC deformability
(RBC-df), and that basal plasma C-peptide concentration
has a beneficial effect on RBC-df by a mechanism involv-
ing Na,K-ATPase [1], we do not believe that C-peptide
deficiency plays a role in our study.
The effect of absolute C-peptide deficiency on RBC-df
has been reported in type 1 diabetic subjects [2]. Fur-
thermore, significantly reduced (but not absent) levels of
C-peptide have been shown to occur only in type 2 di-
abetic subjects who require insulin treatment, and that
C-peptide levels are normal in type 2 subjects who do not
require insulin for glucose control. All diabetic subjects in
our study were type 2, and none required insulin to con-
trol blood glucose. We measured RBC-df in two groups
of nondiabetic subjects with renal disease who served as
control. In these nondiabetic control subjects there was
significant impairment in RBC-df. In fact, impairment in
RBC-df in these subjects with end-stage renal disease (on
maintenance hemodialysis) was not different from their
diabetic counterparts.
Although C-peptide was not measured in our study, we
presume that its concentration was not deficient in either
our nondiabetic control or non–insulin-requiring type 2
diabetic subjects.
